Melanoma of the eye: Preclinical tests show path toward treatment
(University of Alabama at Birmingham) A preclinical study offers hope for treatment of uveal melanoma, a rare and deadly cancer of the eye. A small molecule inhibitor has been identified that dampens the potent drivers of this tumor. In mouse models, the inhibitor strongly limited primary disease in the eye and metastatic tumor dissemination to the liver, and animals survived longer, without overt side effects. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 14, 2021 Category: Cancer & Oncology Source Type: news
Oncotarget: Piperlongumine promotes death of retinoblastoma cancer cells
(Impact Journals LLC) These Oncotarget findings suggest that PL reduces tumor growth and induces cell death by regulating the cell cycle (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 31, 2021 Category: Cancer & Oncology Source Type: news
Small uveal melanomas 'not always harmless', ground breaking study finds
(University of Liverpool) A new article from Liverpool ocular researchers demonstrates that small uveal (intraocular) melanomas are not always harmless, as the current paradigm suggests. Instead, a reasonable proportion of them have molecular genetic alterations, which categorises them as highly metastatic tumours. The article recommends that they should not be observed but rather treated immediately, to improve patients' chances of survival. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 19, 2021 Category: Cancer & Oncology Source Type: news
By age 10, retinoblastoma patients' learning and life skills rebound
(St. Jude Children's Research Hospital) St. Jude Children's Research Hospital researchers studied how retinoblastoma survivors fared years later at home and at school. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 6, 2021 Category: Cancer & Oncology Source Type: news
New Hope Against a Rare but Incurable Eye Cancer
A cutting-edge experimental drug cuts nearly in half the risk of death among patients with a rare but aggressive cancer of the eye. (Source: WebMD Health)
Source: WebMD Health - April 20, 2021 Category: Consumer Health News Source Type: news
New Hope Against a Rare but Incurable Eye Cancer
(Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - April 20, 2021 Category: Cancer & Oncology Tags: Family Medicine, Nursing, Oncology, Ophthalmology, Pharmacy, Research, News, Source Type: news
New Hope Against a Rare but Incurable Eye Cancer
TUESDAY, April 20, 2021 -- A cutting-edge experimental drug cuts nearly in half the risk of death among patients with a rare but aggressive cancer of the eye, new clinical trial data show.
Tebentafusp has now become the first drug shown to improve... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - April 20, 2021 Category: General Medicine Source Type: news
New Hope Against a Rare but Incurable Eye Cancer
Title: New Hope Against a Rare but Incurable Eye CancerCategory: Health NewsCreated: 4/20/2021 12:00:00 AMLast Editorial Review: 4/20/2021 12:00:00 AM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - April 20, 2021 Category: Cancer & Oncology Source Type: news
Tebentafusp improves OS: A First in Metastatic Uveal Melanoma Tebentafusp improves OS: A First in Metastatic Uveal Melanoma
First-line tebentafusp significantly improved overall survival (OS) when compared with immunotherapy or chemotherapy in patients with metastatic uveal melanoma in a phase 3 trial.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - April 16, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
Penn spinout Linnaeus Therapeutics gets key FDA designation
A South Jersey biopharmaceutical firm spun out of the University of Pennsylvania got a boost Thursday when the Food and Drug Administration granted orphan drug designation for the company's lead new drug candidate.
Linnaeus Therapeutics of Haddonfield received the designation for LNS8801. The experimental treatment is for patients with metastatic uveal melanoma, a rare cancer that occurs within the eye.
The FDA's Office of Orphan Drug Products grants orphan status to support drug candidates targeting… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - March 12, 2021 Category: Biotechnology Authors: John George Source Type: news
Conjunctival Melanoma May Be Attributed to UV Radiation Conjunctival Melanoma May Be Attributed to UV Radiation
According to a new study published in Nature Communications, exposure to ultraviolet radiation can lead to a rare type of eye cancer called conjunctival melanoma.Medscape News UK (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - January 13, 2021 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
Huntsman Cancer Institute researchers identify promising drug combination for melanoma
This study was published in the journalClinical Cancer Research. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 3, 2020 Category: Cancer & Oncology Source Type: news
Eye cancer: Shadows, flashes of light, or wiggly lines in your vision could be early signs
EYE cancer is a general term that includes different cancer types with different parts of the eye. Knowing the early signs of the disease will allow for earlier treatment. What to look out for? (Source: Daily Express - Health)
Source: Daily Express - Health - November 27, 2020 Category: Consumer Health News Source Type: news
What Is the Survival Rate of Retinoblastoma?
Title: What Is the Survival Rate of Retinoblastoma?Category: Diseases and ConditionsCreated: 10/22/2020 12:00:00 AMLast Editorial Review: 10/22/2020 12:00:00 AM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - October 22, 2020 Category: Cancer & Oncology Source Type: news
Does Retinoblastoma Cause Blindness?
Title: Does Retinoblastoma Cause Blindness?Category: Diseases and ConditionsCreated: 10/21/2020 12:00:00 AMLast Editorial Review: 10/21/2020 12:00:00 AM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - October 21, 2020 Category: Cancer & Oncology Source Type: news
